Ortho Pharmaceutical Corporation

Other

University of Pennsylvania

Soligenix, Inc.

Alfonso J Tobia

Victor T Bandurco

Robert Falotico

Seymour D Levine

Dennis M Mulvey

Ramesh M Kanojia

Stanley Charles Bell

Charles F Schwender

Jeffery B Press

John H Dodd

Donald W Combs

Bernard E Cabana

Alain H Rook

Venkata Vadlapatla

Ronald H Connolly

Floyd Eliot Fox

The present invention provides a method for making hypericin comprising the steps of converting a protohypericin to a protohypericin salt, and irradiating the protohypericin salt with visible light to form hypericin. The present invention also provides an apparatus comprising a transparent column having a top end and a bottom end, an inlet attached to the column at the top end to flow reactants into the column, a container attached to the column at the bottom end; and a visible light source positioned to cast light on to the column. The present invention further provides a method for making hypericin using said apparatus.

Methods for preparing hypericin

The invention provides methods of using photoactivated hypericin compounds which, when photoactivated using visible or UV-A light, are useful for treating numerous diseases and disorders in mammals. The compounds of the invention are useful for inhibiting the proliferation and accumulation of mammalian leukocytes and for inducing apoptosis in mammalian leukocytes.

Photoactivated hypericin and the use thereof

Substituted 3-isoquinolinol compounds of the general formula ##STR1## that exhibit cardiotonic, renal vasodilating and phosphodiesterase fraction III properties are pharmacologically active in the treatment of cardiac conditions. Methods for synthesizing and using those compounds are described.

Isoquinolinol compounds having cardiotonic and phosphodiesterase

Substituted 3-isoquinolinol compounds of the general formula ##STR1## that exhibit cardiotonic and/or phosphodiesterase fraction III inhibiting properties and/or renal vasodilating are pharmacologically active in the treatment of cardiac conditions. Methods for synthesizing and using those compounds are described.

4-nitrogen substituted isoquinolinol compounds having cardiotonic,

Novel substituted-3-(4-phenyl-1-piperazinyl)alkyl quinazolin-2,4-(1H,3H)diones are described. These compounds are useful as antihypertensive agents.

Substituted 3-(4-phenyl-1-piperazinyl)alkylquinazolin-2,4-(1H,3H)

Quinazoline derivatives having an oxy substituent in 5 and 6 positions are described. The novel quinazoline derivatives are useful as cardiotonic agents.

Substituted 5,6-dialkoxyquinazoline derivatives

Quinazolinone derivatives having an oxy substituent in the 5- and 6-positions are disclosed. The quinazolinone derivatives are useful as cardiovascular agents.

5,6-dialkoxy-4-imino-2(1H)quinazolinone derivatives

The synthesis of substituted 2(1H)-quinazolinone-1-alkanoic acids and their esters is described. The novel quinazolinones are renal vasodilators and as such reduce vascular resistance to renal blood flow. The quinazolinones are useful as cardiovascular agents.

Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters

The synthesis of 5,6-dioxy substituted quinazolinediones is described. The novel quinazolinediones are useful as cardiotonic agents.

Substituted quinazolinediones

The synthesis of substituted quinazolinones is described. The novel quinazolinones are renal vasodilators and thereby increase renal blood flow, and are useful as cardiovascular agents.

Ortho substituted dihydroxy-2(1H)quinazolinone-1-alkanoic acids

A process for preparing 4-alkyl-2(1H)quinazolinone-1-alkanoic acid derivatives is described. The 4-alkyl-2(1H)quinazolinones are useful as cardiovascular agents.

3,4-Dialkoxy-2-alkylcarbonyl analino compounds

A process for preparing 4-alkyl-2-(1H) quinazolinone-1-alkanoic acid derivatives is described. The 4-alkyl-2-(1H) quinazolinones are useful as cardiovascular agents.

Growing community of inventors

Doylestown, PA, United States of America

Alfonso J Tobia